Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. (Q47994395)

From Wikidata

Jump to navigation Jump to search

scientific article published in November 2013

Language	Label	Description	Also known as
English	Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.	scientific article published in November 2013

Statements

scholarly article

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. (English)

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

author name string

Koji Sakata

1

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Manabu Hayakawa

2

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Yuichiro Yano

3

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Noboru Tamaki

4

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Naoto Yokota

5

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Takuma Eto

6

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Reiko Watanabe

7

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Naoteru Hirayama

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Takeshi Matsuo

9

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Kazuo Kuroki

10

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Seiji Sagara

11

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Osamu Mishima

12

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Masahiro Koga

13

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Naoto Nagata

14

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Yuri Nishino

15

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Kazuo Kitamura

16

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Kazuomi Kario

17

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Masayoshi Takeuchi

18

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Sho-ichi Yamagishi

19

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

publication date

1 November 2013

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

29

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

624-630

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

8

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

RAGE biology, atherosclerosis and diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

The RAGE axis: a fundamental mechanism signaling danger to the vulnerable vasculature

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Diagnosis and Classification of Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Revised equations for estimated GFR from serum creatinine in Japan

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Soluble Levels of Receptor for Advanced Glycation Endproducts (sRAGE) and Coronary Artery Disease

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

21 January 2018

Increased serum HMGB1 level is associated with coronary artery disease in nondiabetic and type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble receptor for AGE (RAGE) is a novel independent predictor of all-cause and cardiovascular mortality in type 1 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

7 January 2021

based on heuristic

inferred from DOI database lookup

Sitagliptin augments protective effects of GLP-1 against advanced glycation end product receptor axis in endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

7 January 2021

based on heuristic

inferred from DOI database lookup

Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2437

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.2437

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

1 reference

Europe PubMed Central

7 February 2018

http://europepmc.org/abstract/MED/23861159

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47994395&oldid=1446574521"